The American Legion Invites Veterans to Share VA Experiences at Mobile, AL Town Hall Meeting

WASHINGTON, March 30, 2017 /PRNewswire-USNewswire/ — The American Legion, the nation’s largest and most influential veterans service organization, invites all veterans in Mobile, Ala., and their family members to a town hall meeting to discuss their VA care.

The meeting will be held at 7 p.m. on Monday, April 3, at the USS Alabama Battleship Memorial Park, 2703 Battleship Parkway, Mobile, AL, 36602.

The town hall event is one of about a dozen that the Legion will conduct around the United States this year. The Legion hosts these events to hear feedback from veterans about the quality of health care they receive at their local VA facility.

Representatives from The American Legion Department of Alabama, The American Legion National Headquarters office in Washington, D.C., and representatives from VA and members of the Alabama congressional delegation will be in attendance.

Contact:
Johnathon Clinkscales, Media Relations Specialist
(240) 515-8786 
jclinkscales@legion.org

About The American Legion

With a current membership of over 2 million wartime veterans, The American Legion was founded in 1919 on the four pillars of a strong national security, veterans affairs, Americanism, and youth programs. Legionnaires work for the betterment of their communities through more than 13,000 posts across the nation.

 

SOURCE The American Legion

The American Legion Invites Veterans to Share VA Experiences at Mobile, AL Town Hall Meeting

WASHINGTON, March 30, 2017 /PRNewswire-USNewswire/ — The American Legion, the nation’s largest and most influential veterans service organization, invites all veterans in Mobile, Ala., and their family members to a town hall meeting to discuss their VA care.

The meeting will be held at 7 p.m. on Monday, April 3, at the USS Alabama Battleship Memorial Park, 2703 Battleship Parkway, Mobile, AL, 36602.

The town hall event is one of about a dozen that the Legion will conduct around the United States this year. The Legion hosts these events to hear feedback from veterans about the quality of health care they receive at their local VA facility.

Representatives from The American Legion Department of Alabama, The American Legion National Headquarters office in Washington, D.C., and representatives from VA and members of the Alabama congressional delegation will be in attendance.

Contact:
Johnathon Clinkscales, Media Relations Specialist
(240) 515-8786 
jclinkscales@legion.org

About The American Legion

With a current membership of over 2 million wartime veterans, The American Legion was founded in 1919 on the four pillars of a strong national security, veterans affairs, Americanism, and youth programs. Legionnaires work for the betterment of their communities through more than 13,000 posts across the nation.

 

SOURCE The American Legion

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

     (Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )

     (Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented „Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added „Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudré-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

SOURCE SYMETIS SA

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

(Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudre-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

(Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudre-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

Maui Wowi Sets Sights on Arizona for Expansion

SCOTTSDALE, Ariz., March 30, 2017 /PRNewswire/ — After settling in to its new home base in Scottsdale, Arizona, Maui Wowi® Hawaiian Coffees & Smoothies (www.MauiWowi.com) is targeting The Grand Canyon State for franchise expansion in 2017. The Hawaiian-themed mobile beverage franchise was acquired by Kahala Brands™ in late 2015 and is now looking to expand with multi-unit franchisees. The brand projects opening 15 units throughout Arizona in the next year.

Already working toward its goal of 15 new mobile carts, Maui Wowi has spent the first few months of 2017 securing contracts at Salt River Fields at Talking Stick® in Scottsdale and Chase Field in Phoenix. Through strategic franchise partnerships, the company is looking to follow up on its early success by opening its signature mobile tiki huts, known as Ka’anapali Carts, in entertainment venues, sporting arenas and universities, while expanding its footprint at spring training.

„With the entire Kahala Brands ‚ohana right down the road, including Operations, Marketing and Research & Development, many community-oriented entrepreneurs will appreciate the convenience of finding the brand’s Headquarters close by,” said John Wuycheck, senior vice president of franchise development at Kahala Brands. „Most importantly, Arizona is blessed with beautiful weather, numerous indoor and outdoor events during every season, great universities and a bustling economy, making it ripe for Maui Wowi expansion.”

Targeted development areas for the premium coffee and blended fruit smoothie franchise include Phoenix and the nearby Scottsdale and Tempe communities, Tucson, Flagstaff and Yuma. The company is actively seeking multi-unit operators who are passionate about the Aloha Spirit and committed to providing an outstanding guest experience. Franchise prospects should have a minimum of $100,000 net worth and $75,000 in liquid capital.

The versatile mobile carts are easily transportable and fully equipped to blend smoothies and brew premium Hawaiian coffee on location. Additionally, Wuycheck notes that one perk of the Maui Wowi franchise opportunity is that there are no set territories. However, franchisees can protect events, allowing them to return year after year. This provides franchisees with protection without restriction and the flexibility to take their business to the people.

For more information on the Maui Wowi franchise opportunity, visit www.mauiwowifranchise.com.

About Maui Wowi
Since 1982, Maui Wowi® has embraced the Hawaiian culture and has been serving paradise in a cup since the day it began, over 30 years ago. From event carts, mall kiosks and stand-alone retail locations, Maui Wowi offers premium smoothies, as well as gourmet Hawaiian coffees and espresso beverages. The company maintains strong community involvement through fundraising efforts by its franchisees, in addition to Team Karma; an initiative that promotes corporate responsibility and giving back to the community. The brand has more than 450 operating units and an online store, Shop.MauiWowi.com. In November 2015, Maui Wowi was acquired by Kahala Brands™, one of the fastest growing franchising companies in the world with a portfolio of 22 quick-service restaurant brands and approximately 2900 locations in 28 countries.

For more information about Maui Wowi, visit www.MauiWowi.com.

For more information about Kahala Brands, visit www.KahalaBrands.com.

 

SOURCE Maui Wowi

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

     (Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )

     (Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudré-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

Gynesonics Names James Sparks Vice President of Manufacturing

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic uterine fibroids, today announced that medical device executive James Sparks has been named Vice President of Manufacturing, effective immediately. Mr. Sparks reports directly to Chief Operating Officer Jordan Bajor.

Mr. Sparks has more than 26 years of experience in the medical device industry focused on manufacturing and engineering management. Most recently, from September 2013 to March 2016, he served as Vice President of Manufacturing and Engineering at Tridien Medical, a manufacturer of patient positioning devices and support surfaces to assist caregivers in preventing and treating pressure ulcers. Mr. Sparks’ responsibilities at Tridien included managing three domestic manufacturing facilities with more than 300 employees. Prior to that he performed senior manufacturing/operations leadership roles with Class III implantable heart valves/transcatheter delivery systems (Medtronic), Class II therapeutic laser systems (BIOLASE), Class II/III cardiology and electrophysiology products (J&J/Biosense Webster). He began his career with Baxter/Edwards Life Sciences as a manufacturing/packaging engineer.

“James’ impressive track record in leading the growth and development of medical device manufacturing organizations includes both domestic and off shore operations,” Jordan Bajor explained. “He has demonstrated expertise in cellular manufacturing, demand flow and lean operations techniques. Most importantly, he has applied his skills and experience in successfully supporting rapid commercial growth with the most rigorously regulated medical devices.”

Chris Owens, Gynesonics President and CEO, added: “James has tremendous experience in scaling high growth medical devices, reducing costs, simplifying process while maintaining the highest level of quality. These skills have been developed and utilized at companies which are benchmarked for manufacturing excellence in medical technology. His expertise at ramping manufacturing organizations is an essential addition to our management team. James will continue to develop our manufacturing systems and processes while implementing our global manufacturing plan to support the global launch and rapid uptake of our Sonata® System. We are pleased to have James join the team.”

Mr. Sparks has a B.S. in Engineering Technology from West Coast University and a MBA in Technology Management from the University of Phoenix. He completed six sigma training and implementation with Johnson & Johnson and served for four years in the U.S. Air Force as a Metrologist.

About Sonata System

The Sonata® System, the next generation of Gynesonics’ technology platform (the previous generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata System, including the SMART Targeting Guide, enables the operator to target fibroids and optimize ablations within them. Sonata System’s design provides a straightforward, transcervical access for a uterus, preserving incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. In October 2014, Gynesonics announced FDA approval of the SONATA IDE pivotal trial for their latest generation Sonata™ System.

About Gynesonics

Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata™ System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata™ System is CE Marked and approved for sale in the European Union. Sonata™ System is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.

Maui Wowi Sets Sights on Arizona for Expansion

Hawaiian-Themed Beverage Franchise Reveals Development Plans for Home Market in 2017

SCOTTSDALE, Ariz., March 30, 2017 /PRNewswire/ — After settling in to its new home base in Scottsdale, Arizona, Maui Wowi® Hawaiian Coffees & Smoothies (www.MauiWowi.com) is targeting The Grand Canyon State for franchise expansion in 2017. The Hawaiian-themed mobile beverage franchise was acquired by Kahala Brands™ in late 2015 and is now looking to expand with multi-unit franchisees. The brand projects opening 15 units throughout Arizona in the next year.

Already working toward its goal of 15 new mobile carts, Maui Wowi has spent the first few months of 2017 securing contracts at Salt River Fields at Talking Stick® in Scottsdale and Chase Field in Phoenix. Through strategic franchise partnerships, the company is looking to follow up on its early success by opening its signature mobile tiki huts, known as Ka’anapali Carts, in entertainment venues, sporting arenas and universities, while expanding its footprint at spring training.

“With the entire Kahala Brands ‘ohana right down the road, including Operations, Marketing and Research & Development, many community-oriented entrepreneurs will appreciate the convenience of finding the brand’s Headquarters close by,” said John Wuycheck, senior vice president of franchise development at Kahala Brands. “Most importantly, Arizona is blessed with beautiful weather, numerous indoor and outdoor events during every season, great universities and a bustling economy, making it ripe for Maui Wowi expansion.”

Targeted development areas for the premium coffee and blended fruit smoothie franchise include Phoenix and the nearby Scottsdale and Tempe communities, Tucson, Flagstaff and Yuma. The company is actively seeking multi-unit operators who are passionate about the Aloha Spirit and committed to providing an outstanding guest experience. Franchise prospects should have a minimum of $100,000 net worth and $75,000 in liquid capital.

The versatile mobile carts are easily transportable and fully equipped to blend smoothies and brew premium Hawaiian coffee on location. Additionally, Wuycheck notes that one perk of the Maui Wowi franchise opportunity is that there are no set territories. However, franchisees can protect events, allowing them to return year after year. This provides franchisees with protection without restriction and the flexibility to take their business to the people.

For more information on the Maui Wowi franchise opportunity, visit www.mauiwowifranchise.com.

About Maui Wowi
Since 1982, Maui Wowi® has embraced the Hawaiian culture and has been serving paradise in a cup since the day it began, over 30 years ago. From event carts, mall kiosks and stand-alone retail locations, Maui Wowi offers premium smoothies, as well as gourmet Hawaiian coffees and espresso beverages. The company maintains strong community involvement through fundraising efforts by its franchisees, in addition to Team Karma; an initiative that promotes corporate responsibility and giving back to the community. The brand has more than 450 operating units and an online store, Shop.MauiWowi.com. In November 2015, Maui Wowi was acquired by Kahala Brands™, one of the fastest growing franchising companies in the world with a portfolio of 22 quick-service restaurant brands and approximately 2900 locations in 28 countries.

For more information about Maui Wowi, visit www.MauiWowi.com.

For more information about Kahala Brands, visit www.KahalaBrands.com.

 

SOURCE Maui Wowi

Picture-Perfect Viewing with Do-Anything Versatility: New Philips Ultra Wide Color LCD Display

• 27-inch Quad HD display combines performance with elegance
• Better-than-ever colour gamut: 132% sRGB, 114% NTSC
• Optimal connectivity and superb sound

Amsterdam, 30 March 2017 – MMD, the leading technology company and brand license partner for Philips Monitors, announces a new 27-inch flat screen E-Line display that steps up performance and viewing quality for the many and varied activities of home users. With Quad HD resolution, the latest Ultra Wide Color technology, and stunning looks for the living space, the new 276E8FJAB display offers crisp imaging and rich, vivid colours that inspire creativity and generate a true-to-life viewing experience.

Upping the benchmarks for mainstream quality
“Displays in the home are expected to do a plethora of things – people use them for everything from checking social media and catching up on office work, to editing and producing videos, streaming multimedia from a variety of sources, and connecting with friends and relatives anywhere in the world,” comments Artem Khomenko, Product Manager Philips monitors Europe at MMD. “The latest 27-inch flat screen display is part of an extensive line-up that is designed to do all these things and more, raising the benchmark on viewing quality and convenient connectivity, and giving users the reassurance of a first-class brand at a price point that offers compelling value.”

Ideal for users who are looking for slick performance and elegant design for their living space, the new display offers much more than the standard features and specs. Colour performance is outstanding: With advanced Ultra Wide Color technology, the display supports a colour gamut that is now wider than ever – 114% NTSC based on CIE1976 and 132% sRGB based on CIE 1931, which far exceeds the typical 72% NTSC and 99% sRGB. Ultra Wide Color extends the range of perceptible colours on the screen, a feature that makes the display a valuable tool for activities that benefit from accurate colour reproduction such as home shopping (shoppers see the exact colour of the products they are ordering), as well as watching or editing photos and videos. Complementing its colour abilities, the 276E8FJAB also features Quad HD resolution with 2560 x 1440 pixels for crystal-clear images. Its high-performance wide-view panel supports the high density pixel counts of sources such as DisplayPort and HDMI (supported by the new display), and the extra-wide viewing of 178 degrees makes it possible to view the display from almost any angle.

Features to make great quality even better
With a range of features to automatically optimise visuals, the display fine-tunes the reproduction for an even better viewing experience: Philips SmartContrast and SmartImage Lite technologies analyse the screen content, automatically making adjustments in real time to contrast, colours, image sharpness and backlight intensity to suit what is shown on the screen at the time. Flicker-free technology minimises potential eye fatigue with a new solution that regulates brightness and reduces flicker for more comfortable viewing.
In line with its all-round versatility, the display also provides excellent sound, with two integrated stereo speakers for crisp audio reproduction when watching videos or making video calls.

Slim elegance
The overall elegance of the design makes the display a stylish addition to any room. The design is enhanced by edge-to-edge glass and ultra-narrow borders: as well as creating a seamless appearance, the slim borders maximise the viewing space on the screen and minimise distraction for the eyes.

The new Philips 276E8FJAB E-Line display, with an RRP of £339, will be available in May 2017.


Technical Specifications:
Specification Philips 276E8FJAB display
LCD panel type IPS technology
Backlighting technology W-LED
Panel size 27 inch / 68.6 cm
Aspect ratio 16:9
Optimum resolution 2560 x 1440 @ 60Hz
Viewing angle 178° (H) / 178° (V), @ C/R > 10
Brightness 350 cd/m²
Display colours 16.7 million
Colour gamut (typical) NTSC 114% (based on CIE 1976)
sRGB 132% (based on CIE 1931)
Picture enhancement SmartImage Lite
Convenience • Built-in Speakers: 3 W x 2
• Kensington lock
• Plug & Play Compatibility: DDC/CI, Mac OS X, sRGB, Windows 10 / 8.1 / 8 / 7
Connectivity • Signal Input: VGA (Analog), DisplayPort 1.2, HDMI 1.4
• Sync Input: Separate Sync, Sync on Green
• Audio (In/Out): PC audio-in, Headphone out
Stand • Tilt: -5/20 degree
Sustainability • Environmental and energy: EnergyStar 7.0, EPEAT Silver, RoHS, Lead-free, Mercury Free
• Recyclable packaging material: 100 %
Compliance and standards Regulatory Approvals: CE Mark, FCC Class B,
TCO certified, WEEE, CECP, CU, EPA, RCM
Cabinet • Colour: Black & Gunmetal
• Finish: Glossy

About MMD
MMD is a wholly owned company of TPV established in 2009 through a brand license agreement with Philips. MMD exclusively markets and sells Philips branded LCD displays worldwide. By combining the Philips brand promise with TPV’s manufacturing expertise in displays, MMD uses a fast and focused approach to bringing innovative products to market. MMD serves the Western European markets from its headquarters in Amsterdam. The Eastern European and CIS markets are served by a local office in Prague. Through its network of local sales teams MMD works with all major IT distributors and resellers. The company’s design and development centre is located in Taiwan. www.mmd-p.com

Press contact:
united communications GmbH
Elena Strzelczyk
Rotherstr. 19
10245 Berlin
Tel.: +49 30 7890760
Philips.Displays@united.de

Company contact Europe:
MMD
Ivilina Boneva
Prins Bernhardplein 200 6th floor
1097 JB Amsterdam
Tel.: +31 20 5046945
Ivilina.Boneva@tpv-tech.com

This release was published on openPR.